Physician profile
Rola Saad
NPI 1679585400
$9,713.68
in general payments reported to CMS, 2019-2025
45 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,220 · 2020: $779 · 2021: $1,244 · 2022: $1,504 · 2023: $1,520 · 2024: $1,281 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,908 · Education: $59.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,907.51 |
| Education | $59.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $2,990.84 | 2019-2024 | Strensiq |
| Novo Nordisk INC | $886.88 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $856.54 | 2019-2024 | Lupron Depot, Linzess |
| Insulet Corporation | $612.87 | 2019-2024 | Omnipod |
| Glaxosmithkline, LLC. | $450.42 | 2020-2025 | Nucala, Arexvy, Shingrix |
| Tolmar, INC. | $376.25 | 2023-2025 | Jatenzo |
| Sanofi-Aventis U.S. LLC | $347.48 | 2023-2024 | |
| Ascendis Pharma Endocrinology INC | $303.15 | 2022-2024 | |
| Abbott Laboratories | $283.82 | 2020-2023 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $273.69 | 2020-2024 | Gvoke Hypopen |
| Dexcom, INC. | $263.60 | 2020-2023 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $180.25 | 2020-2024 | Tirosint, Licart, Tirosint |
| Tolmar Pharmaceuticals, INC. | $161.42 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $148.18 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $142.88 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rola Saad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.